A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

Hideyuki Akaza, Hirotsugu Uemura, Taiji Tsukamoto, Seiichiro Ozono, Osamu Ogawa, Hideki Sakai, Mototsugu Oya, Mikio Namiki, Satoshi Fukasawa, Akito Yamaguchi, Hiroji Uemura, Yasuo Ohashi, Hideki Maeda, Atsushi Saito, Kentaro Takeda, Seiji Naito

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of enzalutamide were investigated in patients with castration-resistant prostate cancer (CRPC) in Japan through a multicenter phase I/II study. Methods: In phase I, patients with progressive metastatic CRPC received single, then multiple, ascending doses of enzalutamide 80, 160 or 240 mg/day. After assessment of tolerability at multiple doses of 160 mg/day for 4 weeks, post-docetaxel patients with CRPC and measurable disease were enrolled into phase II; receiving long-term administration of enzalutamide 160 mg/day. Results: Nine and 38 patients were enrolled in phase I and II, respectively. During phase I, enzalutamide was well tolerated in each cohort; PK parameters were similar to those of non-Japanese populations in other studies. By week 12, overall response rate was 5.3 % and clinical benefit rate was 47.4 %. Prostate-specific antigen response rate (≥50 % reduction from baseline) was 28.9 %. Treatment-emergent adverse events reported in >20 % of patients in phase II were decreased weight, decreased appetite and constipation. No seizures were observed. Conclusion: Enzalutamide at 160 mg/day was well tolerated, with PK and safety profiles similar to the non-Japanese population. Anti-tumor activity was observed in post-docetaxel Japanese patients with metastatic CRPC. Apparent differences in anti-tumor activity compared with the AFFIRM study (a phase III trial in a diverse population of patients with CRPC post-docetaxel) may be attributed to differences in treatment history prior to starting enzalutamide. Particularly in Japan, the influence of sequence in hormone treatments, including combined androgen blockade therapy, should be considered. Trial registration: ClinicalTrials.gov NCT01284920.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalInternational Journal of Clinical Oncology
DOIs
Publication statusAccepted/In press - 2016 Jan 21

Fingerprint

Castration
docetaxel
Prostatic Neoplasms
Pharmacokinetics
Japan
Population
Safety
Neoplasms
Appetite
Constipation
Therapeutics
Prostate-Specific Antigen
MDV 3100
Androgens
Seizures
History
Hormones
Weights and Measures

Keywords

  • Androgen receptor inhibitor
  • Enzalutamide
  • Metastatic castration-resistant prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology

Cite this

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer. / Akaza, Hideyuki; Uemura, Hirotsugu; Tsukamoto, Taiji; Ozono, Seiichiro; Ogawa, Osamu; Sakai, Hideki; Oya, Mototsugu; Namiki, Mikio; Fukasawa, Satoshi; Yamaguchi, Akito; Uemura, Hiroji; Ohashi, Yasuo; Maeda, Hideki; Saito, Atsushi; Takeda, Kentaro; Naito, Seiji.

In: International Journal of Clinical Oncology, 21.01.2016, p. 1-10.

Research output: Contribution to journalArticle

Akaza, H, Uemura, H, Tsukamoto, T, Ozono, S, Ogawa, O, Sakai, H, Oya, M, Namiki, M, Fukasawa, S, Yamaguchi, A, Uemura, H, Ohashi, Y, Maeda, H, Saito, A, Takeda, K & Naito, S 2016, 'A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer', International Journal of Clinical Oncology, pp. 1-10. https://doi.org/10.1007/s10147-016-0952-6
Akaza, Hideyuki ; Uemura, Hirotsugu ; Tsukamoto, Taiji ; Ozono, Seiichiro ; Ogawa, Osamu ; Sakai, Hideki ; Oya, Mototsugu ; Namiki, Mikio ; Fukasawa, Satoshi ; Yamaguchi, Akito ; Uemura, Hiroji ; Ohashi, Yasuo ; Maeda, Hideki ; Saito, Atsushi ; Takeda, Kentaro ; Naito, Seiji. / A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer. In: International Journal of Clinical Oncology. 2016 ; pp. 1-10.
@article{b9a6c1d6f30b4b29be5456de38b85f2b,
title = "A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer",
abstract = "Background: The safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of enzalutamide were investigated in patients with castration-resistant prostate cancer (CRPC) in Japan through a multicenter phase I/II study. Methods: In phase I, patients with progressive metastatic CRPC received single, then multiple, ascending doses of enzalutamide 80, 160 or 240 mg/day. After assessment of tolerability at multiple doses of 160 mg/day for 4 weeks, post-docetaxel patients with CRPC and measurable disease were enrolled into phase II; receiving long-term administration of enzalutamide 160 mg/day. Results: Nine and 38 patients were enrolled in phase I and II, respectively. During phase I, enzalutamide was well tolerated in each cohort; PK parameters were similar to those of non-Japanese populations in other studies. By week 12, overall response rate was 5.3 {\%} and clinical benefit rate was 47.4 {\%}. Prostate-specific antigen response rate (≥50 {\%} reduction from baseline) was 28.9 {\%}. Treatment-emergent adverse events reported in >20 {\%} of patients in phase II were decreased weight, decreased appetite and constipation. No seizures were observed. Conclusion: Enzalutamide at 160 mg/day was well tolerated, with PK and safety profiles similar to the non-Japanese population. Anti-tumor activity was observed in post-docetaxel Japanese patients with metastatic CRPC. Apparent differences in anti-tumor activity compared with the AFFIRM study (a phase III trial in a diverse population of patients with CRPC post-docetaxel) may be attributed to differences in treatment history prior to starting enzalutamide. Particularly in Japan, the influence of sequence in hormone treatments, including combined androgen blockade therapy, should be considered. Trial registration: ClinicalTrials.gov NCT01284920.",
keywords = "Androgen receptor inhibitor, Enzalutamide, Metastatic castration-resistant prostate cancer",
author = "Hideyuki Akaza and Hirotsugu Uemura and Taiji Tsukamoto and Seiichiro Ozono and Osamu Ogawa and Hideki Sakai and Mototsugu Oya and Mikio Namiki and Satoshi Fukasawa and Akito Yamaguchi and Hiroji Uemura and Yasuo Ohashi and Hideki Maeda and Atsushi Saito and Kentaro Takeda and Seiji Naito",
year = "2016",
month = "1",
day = "21",
doi = "10.1007/s10147-016-0952-6",
language = "English",
pages = "1--10",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",

}

TY - JOUR

T1 - A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

AU - Akaza, Hideyuki

AU - Uemura, Hirotsugu

AU - Tsukamoto, Taiji

AU - Ozono, Seiichiro

AU - Ogawa, Osamu

AU - Sakai, Hideki

AU - Oya, Mototsugu

AU - Namiki, Mikio

AU - Fukasawa, Satoshi

AU - Yamaguchi, Akito

AU - Uemura, Hiroji

AU - Ohashi, Yasuo

AU - Maeda, Hideki

AU - Saito, Atsushi

AU - Takeda, Kentaro

AU - Naito, Seiji

PY - 2016/1/21

Y1 - 2016/1/21

N2 - Background: The safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of enzalutamide were investigated in patients with castration-resistant prostate cancer (CRPC) in Japan through a multicenter phase I/II study. Methods: In phase I, patients with progressive metastatic CRPC received single, then multiple, ascending doses of enzalutamide 80, 160 or 240 mg/day. After assessment of tolerability at multiple doses of 160 mg/day for 4 weeks, post-docetaxel patients with CRPC and measurable disease were enrolled into phase II; receiving long-term administration of enzalutamide 160 mg/day. Results: Nine and 38 patients were enrolled in phase I and II, respectively. During phase I, enzalutamide was well tolerated in each cohort; PK parameters were similar to those of non-Japanese populations in other studies. By week 12, overall response rate was 5.3 % and clinical benefit rate was 47.4 %. Prostate-specific antigen response rate (≥50 % reduction from baseline) was 28.9 %. Treatment-emergent adverse events reported in >20 % of patients in phase II were decreased weight, decreased appetite and constipation. No seizures were observed. Conclusion: Enzalutamide at 160 mg/day was well tolerated, with PK and safety profiles similar to the non-Japanese population. Anti-tumor activity was observed in post-docetaxel Japanese patients with metastatic CRPC. Apparent differences in anti-tumor activity compared with the AFFIRM study (a phase III trial in a diverse population of patients with CRPC post-docetaxel) may be attributed to differences in treatment history prior to starting enzalutamide. Particularly in Japan, the influence of sequence in hormone treatments, including combined androgen blockade therapy, should be considered. Trial registration: ClinicalTrials.gov NCT01284920.

AB - Background: The safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of enzalutamide were investigated in patients with castration-resistant prostate cancer (CRPC) in Japan through a multicenter phase I/II study. Methods: In phase I, patients with progressive metastatic CRPC received single, then multiple, ascending doses of enzalutamide 80, 160 or 240 mg/day. After assessment of tolerability at multiple doses of 160 mg/day for 4 weeks, post-docetaxel patients with CRPC and measurable disease were enrolled into phase II; receiving long-term administration of enzalutamide 160 mg/day. Results: Nine and 38 patients were enrolled in phase I and II, respectively. During phase I, enzalutamide was well tolerated in each cohort; PK parameters were similar to those of non-Japanese populations in other studies. By week 12, overall response rate was 5.3 % and clinical benefit rate was 47.4 %. Prostate-specific antigen response rate (≥50 % reduction from baseline) was 28.9 %. Treatment-emergent adverse events reported in >20 % of patients in phase II were decreased weight, decreased appetite and constipation. No seizures were observed. Conclusion: Enzalutamide at 160 mg/day was well tolerated, with PK and safety profiles similar to the non-Japanese population. Anti-tumor activity was observed in post-docetaxel Japanese patients with metastatic CRPC. Apparent differences in anti-tumor activity compared with the AFFIRM study (a phase III trial in a diverse population of patients with CRPC post-docetaxel) may be attributed to differences in treatment history prior to starting enzalutamide. Particularly in Japan, the influence of sequence in hormone treatments, including combined androgen blockade therapy, should be considered. Trial registration: ClinicalTrials.gov NCT01284920.

KW - Androgen receptor inhibitor

KW - Enzalutamide

KW - Metastatic castration-resistant prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84955312461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955312461&partnerID=8YFLogxK

U2 - 10.1007/s10147-016-0952-6

DO - 10.1007/s10147-016-0952-6

M3 - Article

C2 - 26793974

AN - SCOPUS:84955312461

SP - 1

EP - 10

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

ER -